Characterization of infiltrating macrophages in high glucose-induced peritoneal fibrosis in rats

Molecular Medicine Reports

Volumn 6, Issue 1, 2012, Pages 93-99

  Hu, Wenxue ^a   Jiang, Zongpei ^a   Zhang, Yu ^a   Liu, Qinghua ^a   Fan, Jinjin ^a   Luo, Ning ^a   Dong, Xiuqing ^a   Yu, Xueqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

M1 macrophages; M2 macrophages; Peritoneal fibrosis; Smad; Transforming growth factor

Indexed keywords

CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 2; INTERLEUKIN 4; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; MACROPHAGE; MALE; NONHUMAN; PERITONEAL FIBROSIS; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GLUCOSE; MACROPHAGES; MALE; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

RATTUS;

EID: 84861626081     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.890     Document Type: Article

References (36)

1. Krediet RT: 30 years of peritoneal dialysis development: the past and the future. Perit Dial Int Suppl 2: 35-41, 2007.
2. Oreopoulos DG and Yang X: Long-term survival on peritoneal dialysis is not a dream anymore: lessons from the East. Perit Dial Int 27: 410-412, 2007. (Pubitemid 47202192)
3. Di Paolo N and Sacchi G: The peritoneum during peritoneal dialysis. Perit Dial Int 20: 37-63, 2000.
4. Yung S and Chan TM: Preventing peritoneal fibrosis - insights from the laboratory. Perit Dial Int 23 (Suppl 2): 37-41, 2003.
5. Garosi G, Cappelletti F and Di Paolo N: Fibrosis and sclerosis: different disorders or different stages? Contrib Nephrol 150: 62-69, 2006. (Pubitemid 44155333)
6. Sandoval P, Loureiro J, González-Mateo G, et al: PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. Lab Invest 90: 1517-1532, 2010.
7. Oh EJ, Ryu HM, Choi SY, et al: Impact of low glucose degradation product bicarbonate/lactate-buffered dialysis solution on the epithelial-mesenchymal transition of peritoneum. Am J Nephrol 31: 58-67, 2010.
8. Kim YL: Update on mechanisms of ultrafiltration failure. Perit Dial Int Suppl 2: 123-127, 2009.
9. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 3: 23-35, 2003.
10. Martinez FO, Sica A, Mantovani A and Locati M: Macrophage activation and polarization. Front Biosci 13: 453-461, 2008. (Pubitemid 351599757)
11. Badylak SF, Valentin JE, Ravindra AK, McCabe GP and Stewart-Akers AM: Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A 14: 1835-1842, 2008.
12. Mantovani A, Sica A and Locati M: Macrophage polarization comes of age. Immunity 23: 344-346, 2005. (Pubitemid 41443435)
13. Troidl C, Möllmann H, Nef H, et al: Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med 13: 3485-3496, 2009.
14. Ohri CM, Shikotra A, Green RH, Waller DA and Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33: 118-126, 2009.
15. Holt MP, Cheng L and Ju C: Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol 84: 1410-1421, 2008. (Pubitemid 352774476)
16. Desguerre I, Mayer M, Leturcq F, Barbet JP, Gherardi RK and Christov C: Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol 68: 762-773, 2009.
17. Vidal B, Serrano AL, Tjwa M, et al: Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev 22: 1747-1752, 2008. (Pubitemid 351915499)
18. Nie J, Hao W, Dou X, et al: Effects of Smad7 overexpression on peritoneal inflammation in a rat peritoneal dialysis model. Perit Dial Int 27: 580-588, 2007. (Pubitemid 351176023)
19. Ng YY, Hou CC, Wang W, Huang XR and Lan HY: Blockade of NFκB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int 94: S83-S91, 2005.
20. Wang W, Huang XR, Li AG, et al: Signaling mechanism of TGF-β in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 16: 1371-1383, 2005. (Pubitemid 41716521)
21. Lai KN and Leung JC: Inflammation in peritoneal dialysis. Nephron Clin Pract 116: 11-18, 2010.
22. Kon M, Hirayama S, Horiuchi Y, et al: Profiles of inflammatory markers and lipoprotein subclasses in patients undergoing continuous ambulatory peritoneal dialysis. Clin Chim Acta 411: 1723-1727, 2010.
23. Devuyst O, Margetts PJ and Topley N: The pathophysiology of the peritoneal membrane. J Am Soc Nephrol 21: 1077-1085, 2010.
24. Palomar R, López-Hoyos M, Morales P, et al: Analysis of peritoneal leukocyte population with different dialysis fluids. Clin Nephrol 72: 137-142, 2009.
25. Mehta A, Brewington R, Chatterji M, et al: Infection-induced modulation of m1 and m2 phenotypes in circulating monocytes: role in immune monitoring and early prognosis of sepsis. Shock 22: 423-430, 2004. (Pubitemid 39472566)
26. Osada S, Hamada C, Shimaoka T, Kaneko K, Horikoshi S and Tomino Y: Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol Dial Transplant 24: 3504-3512, 2009.
27. de Souza LF, Jardim FR, Sauter IP, de Souza MM and Bernard EA: High glucose increases RAW 264.7 macrophages activation by lipoteichoic acid from Staphylococcus aureus. Clin Chim Acta 398: 130-133, 2008.
28. Ohashi K, Takahashi HK, Mori S, et al: Advanced glycation end products enhance monocyte activation during human mixed lymphocyte reaction. Clin Immunol 134: 345-353, 2010.
29. Murphy BS, Bush HM, Sundareshan V, et al: Characterization of macrophage activation states in patients with cystic fibrosis. J Cyst Fibros 9: 314-322, 2010.
30. Heymann F, Trautwein C and Tacke F: Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets 8: 307-318, 2009.
31. Mathai SK, Gulati M, Peng X, et al: Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 90: 812-823, 2010.
32. Higashi-Kuwata N, Jinnin M, Makino T, et al: Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 12: 128, 2010.
33. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K and Varga J: Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 121: 41-50, 2003. (Pubitemid 36900453)
34. Tamaki K and Okuda S: Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 139: 44-65, 2003.
35. Piek E, Heldin CH and Ten DP: Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13: 2105-2124, 1999.
36. Massagué J and Wotton D: Transcriptional control by the TGF-β/Smad signaling system. EMBO J 19: 1745-1754, 2000. (Pubitemid 30204386)